Objective. We describe the effectiveness of a prime-boost vaccination regimen using the open-reading frame (ORFF) gene from the LD1 locus of Leishmania donovani.
lular immune response, is a feasible approach to the prevention of this disease.
During the past few years, significant efforts have been directed toward developing vaccines designed to induce potent cellular immunity against Leishmania infections. Purified antigens, subcellular fractions, and avirulent parasites have been used in vaccine candidates, and these vaccines have provided various levels of protection in murine models [5] . Genetic immunization has also been reported to induce protective immunity through major histocompatibility complex (MHC) class I and class II-restricted T cell responses in a variety of experimental mouse models of infection [6, 7] . Although substantial progress has been made toward the development of some types of vaccines, most of the protective responses they induced were short lived. Thus, the induction of protective immunity is complex, because it includes generation of cellular immune responses that are of considerable strength, longevity, and anatomical distribution to effectively fight pathogens.
One promising approach toward the development and maintenance of strong cellular immunity is the heterologous primeboost vaccination strategy, which involves the sequential administration of vaccines that contain different antigens. The synergistic enhancement of immunity to target antigen is reflected in the selective enrichment of antigen-specific T cells and the increased efficacy against pathogen challenge. These increased numbers of T cells push the cellular immune response over certain thresholds that are required to fight certain pathogens [8, 9] . Furthermore, the general avidity of this increased T cell response is enhanced, which presumably increases the efficacy of the T cells [10] .
In animal models, the heterologous prime-boost vaccination strategy has been shown to generate high levels of memory T cells against a variety of pathogens, including Mycobacteriumtuberculosis [8, 9, 11, 12] , HIV, simian immunodeficiency virus [13] [14] [15] , Plasmodium species [16, 17] , Listeria monocytogenes [18] , Ebola virus [19] , hepatitis C virus [20] , herpes simplex virus [21] , and hepatitis B virus [22] . Previous attempts to enhance the protective immune response through the use of the heterologous prime-boost vaccination strategy have been successful against cutaneous leishmaniasis in a murine model [23, 24] .
We have previously examined the ability of the open-reading frame (ORFF) gene from the LD1 locus to induce protective immunity in BALB/c mice infected with L. donovani. The multigene LD1 locus is present on chromosome 35 in all Leishmania isolates examined [25] [26] [27] . The ORFF gene from the LD1 locus is invariably part of the amplified region. The ORFF protein is present in both the promastigote and amastigote forms of the parasite but is preferentially expressed in L. donovani amastigotes [25] . Serum from patients with VL produced antibodies in response to purified recombinant ORFF (rORFF) protein [28] . Our previous studies have shown that immunization with rORFF resulted in partial protection against VL in mice [29] . We have also shown that the protection induced by the administration of an ORFF DNA vaccine is much stronger than that induced by an rORFF protein vaccine [30] . Moreover, it has been well established that heterologous priming with a DNA vaccine followed by boosting with recombinant antigens or viral vectors is much more effective than is using the same vaccine repeatedly [31] [32] [33] [34] . This prompted us to undertake the present study, in which we evaluate the efficacy of a prime-boost vaccination regimen using ORFF as the candidate antigen against L. donovani infection in BALB/c mice. We also analyze the specific antibody production and cytokine patterns displayed after immunization. The primeboost vaccination regimen triggered a significant level of protection against VL in BALB/c mice.
MATERIALS AND METHODS

Mice.
Female BALB/c mice (4-6 weeks old) were obtained from the National Institute of Nutrition, India. All mice were 6-8 weeks old during the study. Mice were handled in accordance with institutional guidelines, and the relevant committee approved the use of mice for this study.
Parasite culture. L. donovani strain AG83 (MHOM/IN/ 1983/AG83) was maintained in BALB/c mice. Amastigotes were isolated from spleens and then transformed into promastigotes in Medium 199 (Sigma) supplemented with 100 U/mL penicillin (Sigma), 100 mg/mL streptomycin (Sigma), and 30% fetal calf serum (FCS) (Gibco/BRL Life Technologies). Freshly transformed promastigotes were cultured at 22ЊC in Medium 199 and 10% heat-inactivated FCS and were then used to infect BALB/c mice.
Source of ORFF antigen. rORFF (GenBank accession no. AAA96728.1) was produced from the full-length fusion clone pET 17b-C14 by induction with isopropyl b-d-1-thiogalactopyranoside followed by sonication and purification using urea gradient, as described elsewhere [29] . Before use in vaccination, batches of antigen were tested for contamination with lipopolysaccharide (LPS) by assaying the antigen's ability to induce expression of NO synthase [35] . No contamination with LPS was detected in such assays (sensitivity, !1 ng/mL LPS; data not shown).
Plasmids. The ORFF DNA expression plasmid designated F/pcDNA 3.1 was previously constructed by inserting the ORFF gene (GenBank accession no. L38571) into a pcDNA 3.1 vector containing a strong cytomegalovirus promoter [32] . pcDNA 3.1 empty vector was used in all control immunization groups. Plasmids were maintained and propagated in Escherichia coli strain DH5a. Endotoxin-free plasmid DNA was isolated using the EndoFree plasmid Giga kit (Qiagen). The purified construct was used for the immunization and protection studies.
Immunization of mice. Female BALB/c mice (6-8 weeks old) were used for all experiments (5 mice/group). Injections were given at the midpoint of the left thigh muscle. For the vaccination, cell proliferation, cytokine production, and antibody response studies, BALB/c mice were injected intramuscularly (im) with either alum plus 100 mg of pcDNA 3.1 diluted in PBS to a final volume of 100 mL (pcDNA/alum), 50 mg of rORFF adsorbed on alum (protein vaccine), or 100 mg of F/ pcDNA 3.1 in PBS (DNA vaccine). Two weeks later, mice in each group were injected im again with the same materials. For the prime-boost vaccination studies, mice were injected im with 100 mg of the DNA vaccine, and, 2 weeks later, these mice were injected im with a booster dose of the protein vaccine. Serum samples were obtained at 2, 4, and 6 weeks after the final booster dose, and spleens were removed aseptically from mice in each group. Serum samples and spleens were used in the analysis of the humoral and cellular responses after immunization.
Assessment of parasite load after challenge. For the vaccination and protection studies, mice were injected im with either 100 mg of pcDNA/alum, 50 mg of the protein vaccine, or 100 mg of the DNA vaccine, and 2 booster doses were given at 2-week intervals. For the prime-boost group, mice were first injected im with 100 mg of F/pcDNA 3.1/PBS and then were given 2 booster doses of 50 mg of the protein vaccine at 2-week intervals. The mice were then challenged 2 weeks after they received the final booster dose. For the challenge studies, 1 ϫ 10 8 stationary-phase promastigotes of L. donovani in 100 mL of PBS were injected intravenously via the tail vein.
After 4 weeks or 8 weeks of infection, mice were euthanized, and liver and spleen touch biopsies were microscopically examined after the slides were fixed and stained with Giemsa. To quantitate levels of infection, Leishman-Donovan units (LDU) were calculated as follows:
no. of amastigotes ϫ weight of tissue (mg) ( ) no. of tissue nuclei [30] . The percentage of reduction in parasite burden was calculated as follows:
LDU in experimental group 100 Ϫ ϫ 100 .
Assessment of protection was performed using 10 mice/group. Five mice from each group were euthanized for determination of parasitemia at 4 weeks and at 8 weeks of infection. The experiments were repeated twice and had similar results. Splenocyte proliferation assay. Mice were immunized as described in Immunization of Mice. Spleens were removed aseptically 2, 4, or 6 weeks after the mice in each group received the final booster dose. Single-cell suspensions were prepared by grinding the spleen with the disk bottom of the plunger from a 10-mL syringe. RPMI 1640 (5-10 mL) was added to the suspension, and the contents were mixed well. The dish was kept undisturbed for 2 min, and the clear supernatant was pipetted out slowly. Cells were pelleted by centrifugation at 4ЊC and 250 g (Sorvall RC-5 centrifuge and HB-4 rotor) for 10 min. Erythrocytes were lysed by washing the pellet once with 0.9% ice-cold ammonium chloride. The remaining cells were resuspended at a density of cells/mL in RPMI 1640 containing 10% 6 2.5 ϫ 10 FCS and then were divided into 200-mL aliquots of cells 5 5 ϫ 10 and were plated onto 96-well plates (Nunc). Cells were incubated in the presence or absence of ORFF (5 mg/mL) for 3 days at 37ЊC in 5% CO 2 . Proliferation was quantified by measurement of the incorporation of 1 mCi of 3 H-labeled thymidine during the last 16 h of the culture with a Wallac liquid scintillation counter (Perkin Elmer). All assays were performed in triplicate, with 5 mice representing each group.
Cytokine assays. The concentrations of IFN-g, interleukin (IL)-4, and IL-12 in culture supernatants were determined as described elsewhere [36] . Briefly, splenocytes were isolated from each group of mice at different intervals after the final booster dose and were resuspended in RPMI 1640 supplemented with 10% FCS. Splenocytes were then incubated in a 96-well flatbottom plate (Nunc) at a density of splenocytes/well 5 5 ϫ 10 with rORFF (5 mg/mL). After 48 h of incubation, supernatants were collected and diluted serially, and cytokine concentrations were quantitated using an Opt EIA kit (Pharmingen) in accordance with the manufacturer's instructions.
Isotype analysis. Serum immunoglobulin isotypes were assayed by ELISA using 100 ng/well of rORFF, isotype-specific secondary antibodies (biotinylated rabbit anti-mouse IgG2a and IgG1), and streptavidin-conjugated horseradish peroxidase (Pharmingen). Briefly, 96-well plates (Immulon-4; Nunc) were coated with 100 ng of rORFF in 50 mL of carbonate buffer (pH 9.2) and incubated overnight at 4ЊC. The plates were washed 3 times with PBS containing 0.05% Tween 20 (PBST) and then blocked by incubation in 200 mL of 5% milk in PBST for 2 h at 37ЊC. Plates were then washed 3 times with PBST. Mouse serum (100 mL) was diluted to a concentration of 1:300-1: 30,000 in PBST and was added to the wells (except for experimental blanks, which were incubated with 5% milk in PBST), and the plates were incubated for 2 h at 37ЊC. The plates were washed 3 times with PBST. The plates were then incubated with 100 mL of a 1:2000 dilution of biotinylated rabbit anti-mouse IgG2a and IgG1 in PBST for 1 h at 37ЊC and washed again with PBST. The plates were then incubated with 1:2000 of streptavidin-conjugated horseradish peroxidase and washed 3 times with PBST. Color was developed by incubation with a 100-mL aliquot of o-phenylenediamine (5 mg/10 mL in 50 mmol/L citrate-phosphate buffer [pH 5.2]) and 10 mL of 30% H 2 O 2 for 30 min. The reaction was then stopped with 50 mL of 2NH 2 SO 4 . The absorbance at 490 nm was determined using a model 7520 microplate reader (Cambridge Technology). All samples were run in triplicate.
Statistical analysis. Results from the different treated groups were compared by Student's t test.
was consid-P ! .05 ered to be statistically significant.
RESULTS
Humoral response after priming with F/pcDNA 3.1. Because the outcome of VL may be determined by the extent of immune system activation, it was of interest to characterize the changes in the immunoglobulin ratios after immunization. Moreover, the antibody isotype provides a convenient surrogate marker of Th1 and Th2 CD4 + T cell differentiation. Therefore, we determined the relationship between Th1 and Th2 responses in the groups of mice immunized as described in Materials and Methods. Serum samples were collected 2, 4, and 6 weeks after the final booster dose, and anti-ORFF-specific IgG1 and IgG2a levels were evaluated in pooled serum samples. Table 1 shows the iso- In vitro splenocyte proliferation in mice after immunization. Mice were immunized twice at 2-week intervals as described in Immunization of Mice. Splenocytes were isolated and cell proliferation was studied 2, 4, and 6 weeks after immunization. Splenocytes from all groups were stimulated with recombinant open-reading frame protein, and incorporation of 3 H-labeled thymidine was determined. The results were calculated after subtraction of the counts per minute obtained from unstimulated naive cells. Dcpm represents the difference in counts per minute measured after incorporation of 3 H-labeled thymidine in each experimental group in the presence of antigen, compared with that in the corresponding unstimulated cells in the absence of antigen. Each sample was examined in triplicate, and results are representative of 2 experiments. * , vs. the protein vaccine group. P ! .001 type profile obtained for the different groups at various time intervals. As is shown in table 1, the DNA vaccine group had the highest IgG2a:IgG1 ratio at 2 weeks after immunization, and the prime-boost group had the next highest ratio. Interestingly, in the prime-boost group, the levels of IgG2a showed a steady increase at 4 weeks after immunization, when it had an IgG2a: IgG1 ratio of 4.0, the highest ratio overall. The levels were maintained until 6 weeks after immunization, whereas the other immunized groups had rapidly decreasing levels of IgG2a. In contrast to the prime-boost group, mice immunized with only the protein vaccine had high levels of IgG1 and comparatively much lower levels of IgG2a. Thus, the prime-boost vaccination regimen seemed to improve the immunogenicity of the protein vaccine formulation, thereby modulating the response toward a Th1 type, which confers resistance to VL.
Antigen-specific proliferative response and sustained levels of IFN-g production in heterologous prime boosting. To analyze the cellular immune response elicited by the prime-boost vaccination regimen, spleens of immunized mice were removed aseptically at 2, 4, and 6 weeks after the final booster dose, and splenocyte proliferation was studied in vitro. Splenocytes from mice immunized with only the protein vaccine did not exhibit increased proliferation when compared with splenocytes from mice immunized with only the DNA vaccine. However, in the prime-boost vaccination studies, priming with a single dose of the DNA vaccine followed by the administration of a booster dose of the protein vaccine augmented the proliferative response by 1.5-1.6-fold, compared with the proliferative response observed in splenocytes from mice immunized with only the protein vaccine at 2 weeks ( ) and 4 weeks (P ! .001) P ! .001 after immunization (figure 1). Because heterologous priming can stimulate and increase the in vitro proliferative response of splenocytes, we next examined the levels of cytokines secreted by these stimulated cells. Concomitantly, splenocytes from mice immunized with the prime-boost vaccination regimen secreted much higher levels of IFN-g than did splenocytes from mice immunized with the protein vaccine ( ) ( figure 2A ). In-P ! .001 terestingly, at 4 weeks after the final booster dose, IFN-g levels in the prime-boost group were even higher than those in the DNA vaccine group ( ) ( figure 2A ). These levels were P ! .01 sustained even 6 weeks after immunization ( ) ( figure  P ! .001  2A) . Similarly, at 4 weeks after immunization, IL-12 levels were enhanced by 1.9-fold in the prime-boost group, compared with levels in the protein vaccine group ( ) (figure 2B). In P ! .001 contrast, IL-4 levels were comparatively lower in the primeboost group than in the protein vaccine group (figure 2C). Inhibition in levels of IL-4 of ∼1.4-9.7-fold was observed in the prime-boost group at 4 weeks ( ) and 6 weeks ( P ! .02 P ! ) after immunization, compared with those in the protein .005 vaccine group.
Durable protection after priming with the DNA vaccine followed by immunization with the protein vaccine. The in vitro splenocyte proliferation and cytokine analysis data suggested that priming with the DNA vaccine resulted in an IFNg-dominant response, compared with that in immunization with the protein vaccine. As a further measure of vaccine efficacy, we investigated whether the prime-boost vaccination regimen could prime the host to respond to an in vivo parasite challenge. Groups of 10 mice each were immunized and challenged as described in Assessment of Parasite Load after Challenge. Immunization with only pcDNA/alum did not result in Figure 2 . Cytokine levels after immunization. Spleens were collected as described in Materials and Methods. Splenocytes were stimulated with recombinant open-reading frame protein, and concentrations of released interferon (IFN)-g (A), interleukin (IL)-12 (B) , and IL-4 (C) in the culture supernatants were determined 2, 4, and 6 weeks after immunization. The cytokine levels were calculated after subtraction of the respective cytokine levels produced by unstimulated cells. decreased parasite load when compared with that in mice injected with only PBS. Therefore, this vaccine was used as a control in all protection studies. Mice immunized with only the protein vaccine had a 45%-60% reduction in parasite burden in spleen and liver after 4 and 8 weeks of challenge, respectively ( figure 3A and 3B) . A comparison of the protective efficacy of the DNA vaccine and the prime-boost vaccination regimen showed similar protection levels in both spleen and liver. The reduction in parasitic burden in these 2 groups of mice was ∼75%-80% after 4 and 8 weeks of challenge, respectively. Prime-boost vaccination regimens containing the DNA vaccine and the protein vaccine increased the protective effect above that achieved in vaccination with only the protein vaccine. However, protection levels were not higher than those achieved in immunization with only the DNA vaccine. Thus, it was clearly evident that a single injection of the DNA vaccine in the prime-boost group was enough to induce an antigenspecific recall response and prime for a characteristically protective Th1 response.
DISCUSSION
Most anti-Leishmania vaccines were formulated on the basis of the increasing understanding of the cellular immunological response to the parasites. Although the clinical manifestations of disease are determined by the species of Leishmania and the host immune response, results of most studies indicate that the outcome of Leishmania infection seems to be dependent on the regulation of the balance between the Th1 and Th2 reactive T cell populations. Thus, activation of the 2 T cell subsets-that is, CD4
+ T helper cells and CD8 + cytotoxic T lymphocytes (CTLs)-is necessary to elicit protection. Other parameters include the Th1-mediating cytokine IL-12 [37] , secretion of high levels of the effector cytokine IFN-g [38] , and induction of the macrophage microbicidal enzyme NO synthase type 2 [39] .
DNA vaccines that stimulate both kinds of T cell subsets have been described. Furthermore, prime-boost vaccination regimens that include DNA priming have been associated with potent CTL and Th1 responses [40, 41] . We have reported elsewhere that immunization of BALB/c mice with rORFF conferred partial protection against challenge with L. donovani promastigotes. Protection was enhanced when ORFF was used as a DNA vaccine. In the present study, we evaluated and compared the protective efficacy of an ORFF-based prime-boost vaccination regimen with that of ORFF protein and DNA vaccines against L. donovani in a murine model of VL.
Our data demonstrate that priming with a single dose of the DNA vaccine had an unequivocally impressive effect in vivo in modulating the response in vaccination with the protein vaccine alone. The prime-boost vaccination regimen resulted in enhanced protection against Leishmania infection (75%-80%), compared with the protection conferred by the protein vaccine (45%-60%), after 4 weeks of challenge. This enhanced reduction in parasitic burden was achieved only because the DNA priming induced specific T cell responses. However, the maximal protective effect did not exceed the efficacy achieved after immunization with only the DNA vaccine.
Several studies have demonstrated that priming with the DNA vaccine followed by boosting with recombinant virus generates enhanced protective immunity in animal models of HIV infection [13] [14] [15] and malaria [16, 17] . The most critical element of the heterologous prime-boost vaccine strategy is the ability of the initial DNA-based vaccines to prime T cells to generate enhanced secondary responses. This is mainly due to their relatively low-level-but persistent-expression of immunogenic proteins in vivo. These T cells may display higher average affinities for MHC peptide molecules after multiple exposures to antigen. Moreover, limiting the doses of antigen may select for T cells that have receptors of increased affinity [42, 43] . Thus, the efficacy of the prime-boost vaccination strategy may be due, in part, to the ability of DNA vaccines to generate high-affinity T cells whose numbers are expanded after the following booster dose.
In the experiments performed here, DNA priming clearly had a profound effect in modulating the immune response, although it did not lead to greater protection than did immunization with only the DNA vaccine. This result is consistent with those of earlier studies in which a prime-boost vaccination regimen consisting of immunization with a DNA vaccine followed by recombinant protein was either equally or less effective in conferring protective immunity to L. major infection than was immunization with only a DNA vaccine [44, 45] . Our results clearly show that the prime-boost vaccination regimen resulted in an enhanced cellular response, compared with that in the protein vaccine group. Although vaccination with rORFF alone resulted in enhanced antibody production, the majority of the antibodies were of the IgG1 subtype. This could be attributed to the fact that the administration of most of the protein-based vaccines results in a humoral response with Th2 characteristics. Furthermore, rORFF was adsorbed on alum, and it is well established that alum by itself results in a biased Th2 response that leads to high IgG1 production [46] . A primeboost vaccination regimen in which immunization with an ORFF DNA vaccine was followed by immunization with an rORFF protein vaccine resulted in antibody titers with a bias toward the Th1-promoting isotype IgG2a. Furthermore, priming with ORFF DNA resulted in enhanced production of IFNg and IL-12, compared with that in other vaccine groups. In contrast, IL-4 remained at minimal levels. Thus, the reduction in parasitic burden achieved after challenge could be correlated with the immune response generated after immunization.
In conclusion, we demonstrate here that a regimen of ORFF DNA priming followed by a booster dose of rORFF protein is effective in triggering protection against VL in an experimental murine model and that this protection correlates with a skewing toward a Th1 type of immune response. Such a regimen, in combination with immunization with other Leishmania antigens, can be very useful for eliciting an enhanced cellular and humoral response and increasing the efficacy of individual antigens in the control of active Leishmania infections.
